Health Care [ 9/12 ] | Pharmaceuticals [ 39/75 ]
NASDAQ | Common Stock
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases.
Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation.
The company was incorporated in 2015 and is headquartered in New York, New York.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 25, 26 | -0.45 | -0.58 Increased by +22.41% |
| Nov 6, 25 | -0.61 | -0.28 Decreased by -117.86% |
| Sep 3, 25 | -1.44 | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 0.00 Decreased by N/A% | -11.47 M Decreased by -126.23% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 25 | 0.00 Decreased by N/A% | -3.56 M Increased by +74.92% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | N/A Decreased by N/A% | -5.09 M Increased by +81.63% | - - |
| Mar 31, 25 | N/A Decreased by N/A% | -5.09 M Increased by +68.50% | - - |
| Dec 31, 24 | 0.00 - | -5.07 M - | Decreased by N/A% - |
| Sep 30, 24 | 0.00 - | -14.18 M - | Decreased by N/A% - |
| Jun 30, 24 | 0.00 - | -27.70 M - | Decreased by N/A% - |
| Mar 31, 24 | 0.00 - | -16.15 M - | Decreased by N/A% - |